Abstract 1464P
Background
Immunotherapy represents an alternative to chemotherapy and clinical trial for squamous cell lung cancer. Due to the underrepresentation of elderly patients in clinical trials, it is not clear whether they derive similar benefit from immunotherapy as their younger patients.
Methods
A retrospective analysis using National Cancer Database (NCDB) was conducted in patients diagnosed with metastatic squamous cell lung carcinoma between 2016 and 2019. Kaplan Meier survival plots were used to examine survival outcome of different age groups: 19-49, 50-79 and 80 and older. Each age group was examined for benefit from chemotherapy (CR), chemotherapy + immunotherapy (CI), immunotherapy (IO), and no treatment (NR). Cox regression analysis was used to identify factors associated with overall survival.
Results
Of the 24,111 patients analyzed, 3,072 were 80 years or older. Patient who received immunotherapy had much better overall survival than those without. The one-year and two- years overall survival in these groups are CI: 52.98%, 18.10%; IO: 46.85%, 16.34%; CR: 40.11%, 10.73% and NR: 11.13%, 3.81% respectively. Although overall survival declined with age, age itself was not responsible for the poor outcome coming with it. No significant interaction effect was found between age and treatment. In multivariate analysis, HR was 1.01; 0.91-1.11; P=0.862 in age 19-49 and HR 1.02; 0.98-1.06, P=0.397 in age 50-79 compared to age 80 year or older (HR 1.0). Different age groups benefited similarly to all treatments. Compared to CR only (HR 1.0), treatment with CI conferred the best survival outcome HR 0.73; 95% CI 0.71-0.76; P<0.001; IO comes in next with HR 0.84 95% CI 0.80-0.88; P<0.001 and NR performed the worst (HR 2.90; 95% CI 2.80-3.0; P<0.001), suggesting that differences in survival is related to factors other than age.
Conclusions
Although immune senescence is of concern in senior patients receiving immunotherapy, older patients with squamous cell lung cancer benefit from treatment with immune therapy and chemotherapy combination, immunotherapy, chemotherapy as much as younger patients. Age itself is not associated with immunotherapy inefficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhonglin Hao, MD.
Funding
In part by the NCI Cancer Center Support Grant P30 CA177558.
Disclosure
Z. Hao: Non-Financial Interests, Institutional, Local PI: Novartis Inc, BeiGene; Other, Personal, Advisory Role: Cardinal Health.
Resources from the same session
1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Presenter: Jin-Ji Yang
Session: Poster session 20
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1382P - Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Presenter: Christian Rolfo
Session: Poster session 20
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Presenter: Guilherme Harada
Session: Poster session 20
1385P - Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Presenter: Monica Chen
Session: Poster session 20
1386P - Validation of MET amplification using next-generation sequencing in lung adenocarcinoma
Presenter: Marta Salido
Session: Poster session 20
1387P - Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study
Presenter: haifeng sun
Session: Poster session 20
1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Presenter: Shirish Gadgeel
Session: Poster session 20